Active Pharmaceutical Ingredients

English Synonyms 1,4-Bis((1,4,8,11-tetraazacyclotetradecan-1-yl)methyl)benzene

Catalog ID99759

CAS NO.110078-46-1

Purity 98%

MDL NumberMFCD05662218

EINEC Molecular FormulaC28H54N8

Molecular Weight 502.782,

Category	Content
Generic Name	Plerixafor
Brand Name	Mozobil
Drug Class	Hematopoietic Stem Cell Mobilizer, CXCR4 Antagonist
Mechanism of Action	Plerixafor is a selective CXCR4 antagonist that blocks the binding of stromal cell-derived factor-1α (SDF-1α) to CXCR4. This interaction helps mobilize hematopoietic stem cells (HSCs) from the bone marrow into the bloodstream.
Indications	– Used in combination with granulocyte colony-stimulating factor (G-CSF) to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with non-Hodgkin’s lymphoma or multiple myeloma.<br>- Investigated for other uses, including wound healing and cancer treatment.
Dosage Forms	Subcutaneous injection (20 mg/mL solution)
Administration	Administered subcutaneously. A healthcare provider will give the injection and monitor the patient for at least 30 minutes to ensure no allergic reaction occurs.
Pharmacokinetics	– Peak plasma concentrations occur within 30 to 60 minutes after subcutaneous injection.<br>- Elimination is primarily renal, with approximately 70% of the dose excreted unchanged in urine within the first 24 hours.<br>- Terminal half-life is between 3 and 5 hours.
Side Effects	– Common: Injection site irritation, nausea, vomiting, diarrhea, headache, dizziness, tiredness, joint pain.<br>- Serious: Allergic reactions (including anaphylactic shock), splenomegaly, splenic rupture.
Precautions	– Not recommended for patients with leukemia.<br>- Use with caution in patients with renal impairment; dose adjustment is required for those with moderate to severe renal impairment.<br>- Pregnancy Category D: May cause fetal harm; effective contraception is advised.<br>- Not recommended for breastfeeding.
Storage	Store at room temperature (15°C to 30°C); protect from light and moisture.
Developer	Genzyme Corporation (a Sanofi company)
Approval Date	Approved by the FDA in December 2008

Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.

If you're ready to take the next step, Leave your message below and we’ll reply soon. 20+ years of chemical manufacturing & export experience, a partner you can trust.